Espejel-Huerta Diana, Antillón-Ferreira Carlos Alberto, Iglesias-Leboreiro José, Bernárdez-Zapata Isabel, Martínez-Ramos Méndez Angélica, Rendón-Macías Mario Enrique
Facultad Mexicana de Medicina, Universidad La Salle, Distrito Federal, México.
Rev Med Inst Mex Seguro Soc. 2016 Jan-Feb;54(1):64-9.
Diabetes is a serious health problem for pediatrics. In pediatric patients control depends on correct insulin administration. The most usual is subcutaneous administration according to the glycemic control. The aim was to analyze the indications for continuous subcutaneous insulin infusion (CSII) in type 1 diabetes mellitus (T1DM) children and adolescents.
It was carried out a descriptive study in patients from 1 to 16 years with T1DM who underwent CSII therapy. The main cause to use this therapy was analyzed, and also if that cause was different regarding age, sex and disease progression.
61 patients underwent CSII therapy. The median age at the beginning of treatment was 9 years old; 43 patients (71.6 %) had more than one year of diagnosis. The main reasons to use CSII were: 42.6 % had to improve their quality of life, 34.4 % had to reduce the high glycemic variability, 13.1 % had to control severe recurrent hypoglycemia, and 9.8 % had to control their HbA1c. For children under 6 years of age (n = 14) the more frequent indication were recurrent hypoglycemia and to improve their quality of life; children from 6 to 12 years of age (n = 27) had to improve their quality of life, and in children over 12 years CSII was indicated for high glycemic variability and severe recurrent hypoglycemia. There was no different indication related between sexes.
Improve their quality of life and reach a better glycemic control were the main reasons to start CSII in our patients.
糖尿病对儿科来说是一个严重的健康问题。在儿科患者中,病情控制取决于正确的胰岛素给药。最常见的是根据血糖控制情况进行皮下给药。目的是分析1型糖尿病(T1DM)儿童和青少年持续皮下胰岛素输注(CSII)的适应证。
对1至16岁接受CSII治疗的T1DM患者进行描述性研究。分析了使用该疗法的主要原因,以及该原因在年龄、性别和疾病进展方面是否存在差异。
61例患者接受了CSII治疗。治疗开始时的中位年龄为9岁;43例患者(71.6%)已确诊超过一年。使用CSII的主要原因是:42.6%的患者为了改善生活质量,34.4%的患者为了降低高血糖变异性,13.1%的患者为了控制严重反复低血糖,9.8%的患者为了控制糖化血红蛋白(HbA1c)。对于6岁以下儿童(n = 14),最常见的适应证是反复低血糖和改善生活质量;6至12岁儿童(n = 27)为了改善生活质量,而12岁以上儿童CSII的适应证是高血糖变异性和严重反复低血糖。性别之间的适应证没有差异。
改善生活质量和实现更好的血糖控制是我们的患者开始使用CSII的主要原因。